首页> 美国卫生研究院文献>Antibiotics >Analogues of a Cyclic Antimicrobial Peptide with a Flexible Linker Show Promising Activity against Pseudomonas aeruginosa and Staphylococcus aureus
【2h】

Analogues of a Cyclic Antimicrobial Peptide with a Flexible Linker Show Promising Activity against Pseudomonas aeruginosa and Staphylococcus aureus

机译:循环抗微生物肽的类似物其具有柔性接头显示对铜绿假单胞菌和金黄色葡萄球菌的有前途的活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The emergence of multi-drug resistant bacteria is becoming a major health concern. New strategies to combat especially Gram-negative pathogens are urgently needed. Antimicrobial peptides (AMPs) found in all multicellular organisms act as a first line of defense in immunity. In recent years, AMPs have attracted increasing attention as potential antibiotics. Naturally occurring antimicrobial cyclic lipopeptides include colistin and daptomycin, both of which contain a flexible linker. We previously reported a cyclic AMP BSI-9 cyclo(Lys-Nal-Lys-Lys-Bip-O Oc-Nal-Lys-Asn) containing a flexible linker, with a broad spectrum of activity against bacterial strains and low hemolytic activity. In this study, improvement of the antimicrobial activity of BSI-9, against the European Committee on Antimicrobial Susceptibility Testing (EUCAST) strains of , , , and was examined. This led to synthesis of eighteen peptide analogues of BSI-9, produced in four individual stages, with a different focus in each stage; cyclization point, hydrophobicity, cationic side-chain length, and combinations of the last two. Specifically the modified compound , exhibited improved activity against and with MIC of 4 µg/mL and 8 µg/mL, respectively, compared to the original BSI-9, which had an MIC of 16–32 µg/mL.
机译:多种耐药细菌的出现正成为一个主要的健康问题。迫切需要打击尤其是革兰阴性病原体的新策略。在所有多细胞生物中发现的抗微生物肽(AMPS)作为豁免的第一道防御。近年来,安培引起了潜在的抗生素越来越受到关注。天然存在的抗微生物环状脂肽包括Colistin和Daptomycin,两者含有柔性接头。我们之前报道了含有柔性接头的循环amp Bsi-9环(Lys-nal-lys-leys-bip-oc-nal-lys-Ac-ann),具有抗细菌菌株和低溶血活性的广谱。在这项研究中,改善了BSI-9的抗菌活性,对抗欧洲抗菌易患性试验(EUCAST)菌株,并检查了。这导致合成BSI-9的十八肽类似物,在四个单独的阶段生产,每个阶段具有不同的焦点;环化点,疏水性,阳离子侧链长度和最后两个组合。具体地,与原始BSI-9相比,改性化合物,分别与肌炎的麦克风和8μg/ ml的MIC具有9μg/ ml和8μg/ ml的改善的活性,其具有16-32μg/ ml的MIC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号